Ranking · Unmet Need
Trial Gap Index
Burden percentile minus active-trial percentile within the same scope. Positive values flag cancers with high mortality burden but comparatively few active trials. A quantitative signal, not an accusation (CLAUDE.md §324). Caveat (Phase 1): trial counts aggregate a cancer and its NCIt descendants only; registrations phrased at a broader level (e.g. "colorectal cancer" for colon and rectal cancer) are attributed to the broader entity, which can overstate the gap of narrower top-level sites.
Computedci-trial-gap-v1unit: percentile pointshigher = worseAll metrics
| Rank | Δ | Cancer | Trial Gap Index (percentile points) | Percentile | Confidence | Sources | Why #n? |
|---|---|---|---|---|---|---|---|
| 1 | = | Malignant Colon Neoplasm | +56.7 | 100 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594524 |
| 2 | = | Malignant Bladder Neoplasm | +23.3 | 96.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594525 |
| 3 | = | Cutaneous Melanoma | +20 | 93.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594526 |
| 4 | = | Malignant Laryngeal Neoplasm | +20 | 90 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594527 |
| 5 | = | Malignant Pancreatic Neoplasm | +10 | 86.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594528 |
| 5 | = | Malignant Vaginal Neoplasm | +10 | 86.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594529 |
| 5 | = | Malignant Vulvar Neoplasm | +10 | 86.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594530 |
| 8 | = | Malignant Esophageal Neoplasm | +3.4 | 76.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594531 |
| 9 | = | Malignant Salivary Gland Neoplasm | +3.3 | 73.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594532 |
| 10 | = | Malignant Kidney Neoplasm | +3.3 | 70 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594534 |
| 10 | = | Malignant Mesothelioma | +3.3 | 70 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594533 |
| 10 | = | Malignant Ovarian Neoplasm | +3.3 | 70 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594535 |
| 13 | = | Malignant Lung Neoplasm | 0 | 60 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594536 |
| 13 | = | Malignant Prostate Neoplasm | 0 | 60 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594537 |
| 13 | = | Malignant Rectal Neoplasm | 0 | 60 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594538 |
| 16 | = | Malignant Thyroid Gland Neoplasm | -3.3 | 50 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594539 |
| 17 | = | Malignant Hypopharyngeal Neoplasm | -3.3 | 46.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594540 |
| 18 | = | Malignant Testicular Neoplasm | -3.4 | 43.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594541 |
| 19 | = | Malignant Breast Neoplasm | -3.4 | 40 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594542 |
| 20 | = | Malignant Liver Neoplasm | -6.6 | 36.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594543 |
| 21 | = | Malignant Penile Neoplasm | -6.7 | 33.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594544 |
| 22 | = | Leukemia | -6.7 | 30 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594545 |
| 23 | = | Malignant Anal Neoplasm | -10 | 26.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594547 |
| 23 | = | Malignant Gastric Neoplasm | -10 | 26.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594546 |
| 25 | = | Hodgkin Lymphoma | -10 | 20 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594548 |
| 26 | = | Non-Hodgkin Lymphoma | -13.3 | 16.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594549 |
| 27 | = | Malignant Central Nervous System Neoplasm | -13.4 | 13.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594550 |
| 28 | = | Malignant Uterine Corpus Neoplasm | -16.6 | 10 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594551 |
| 29 | = | Malignant Cervical Neoplasm | -16.7 | 6.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594552 |
| 30 | = | Multiple Myeloma | -20 | 3.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594553 |
| 31 | = | Malignant Nasopharyngeal Neoplasm | -26.6 | 0 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594554 |
Data updated 16 hours agoSource updated unknown31 eligible entities · inputs hash 8d416fb2a7d47e190a623ef5